The LPA-CDK5-tau Pathway Mediates Neuronal Injury in an in Vitro Model of Ischemia-Reperfusion Insult

Wang Yaya,Zhang Jie,Huang Liqin,Mo Yanhong,Wang Changyu,Li Yiyi,Zhang Yangyang,Zhang Zhaohui
DOI: https://doi.org/10.1186/s12883-022-02694-2
2022-01-01
BMC Neurology
Abstract:Lysophosphatidic acid (LPA) is a common glycerol phospholipid and an important extracellular signaling molecule. LPA binds to its receptors and mediates a variety of biological effects, including the pathophysiological process underlying ischemic brain damage and traumatic brain injury. However, the molecular mechanisms mediating the pathological role of LPA are not clear. Here, we found that LPA activates cyclin-dependent kinase 5 (CDK5). CDK5 phosphorylates tau, which leads to neuronal cell death. Inhibition of LPA production or blocking its receptors reduced the abnormal activation of CDK5 and phosphorylation of tau, thus reversing the death of neurons. Our data indicate that the LPA-CDK5-Tau pathway plays an important role in the pathophysiological process after ischemic stroke. Inhibiting the LPA pathway may be a potential therapeutic target for treating ischemic brain injury.
What problem does this paper attempt to address?